Job alerts from Amunix Operating Inc.
Never miss new job openings
No, I'm not interested
bell icon

Amunix is leveraging our expertise in precision protein engineering to enable the promise of T cell engagers in solid tumors. Our goal is to save cancer patients lives through the development and commercialization of breakthrough therapies that harness the immune system. We have invented XTEN, a validated therapeutic half-life extension technology. Our current focus is Pro-XTEN, a next-generation protease activated pro-drug platform, which enables selective activation of potent cancer therapies in the tumor microenvironment.

Company - Private
$10M to $25M
Small
Multiple locations
General Hospitals, Home Health Care Services Companies, Niche Health Practitioners Companies, Chemical Manufacturers, Pharmaceutical Manufacturers, Scientific Research & Development Firms, Health & Personal Care Retailers
2013